Skip to main content

Drug Interactions between Demulen 1/35 and repotrectinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ethinyl estradiol repotrectinib

Applies to: Demulen 1 / 35 (ethinyl estradiol / ethynodiol) and repotrectinib

Repotrectinib may reduce the blood levels of ethinyl estradiol, which may make it less reliable as a form of birth control. Alternative methods of birth control should be used during treatment with repotrectinib and for 2 months after stopping treatment to avoid unintended pregnancy. This is particularly important because repotrectinib may cause fetal harm. Talk to your gynecologist or other healthcare professional for help in selecting an effective method of birth control that is best for you. Men with female partners of reproductive potential receiving repotrectinib should use a condom during the treatment period and for 4 months after stopping treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Major

ethynodiol repotrectinib

Applies to: Demulen 1 / 35 (ethinyl estradiol / ethynodiol) and repotrectinib

Repotrectinib may reduce the blood levels of ethynodiol, which may make it less reliable as a form of birth control. Alternative methods of birth control should be used during treatment with repotrectinib and for 2 months after stopping treatment to avoid unintended pregnancy. This is particularly important because repotrectinib may cause fetal harm. Talk to your gynecologist or other healthcare professional for help in selecting an effective method of birth control that is best for you. Men with female partners of reproductive potential receiving repotrectinib should use a condom during the treatment period and for 4 months after stopping treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Major

repotrectinib food

Applies to: repotrectinib

Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with repotrectinib as they may increase the blood levels of repotrectinib. This may increase the risk and/or severity of side effects such as dizziness, tiredness, muscle pain, nausea, change in your sense of taste, feeling numbness or tingling in your arms or legs, constipation, trouble with balance, shortness of breath, problems with thinking such as forgetfulness or confusion and hallucinations, as well as more serious side effects such severe or life-threatening inflammation of the lungs and liver injury. Talk to your doctor if you have any questions or concerns. Your doctor may be able to provide alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Minor

ethinyl estradiol food

Applies to: Demulen 1 / 35 (ethinyl estradiol / ethynodiol)

Information for this minor interaction is available on the professional version.

Minor

ethinyl estradiol food

Applies to: Demulen 1 / 35 (ethinyl estradiol / ethynodiol)

Information for this minor interaction is available on the professional version.

Minor

ethynodiol food

Applies to: Demulen 1 / 35 (ethinyl estradiol / ethynodiol)

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer